Clal Biotechnology reported ILS6.66M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Arca Biopharma USD 16.63M 1.26M Mar/2026
aTyr Pharma USD 11.7M 101.49M Mar/2026
Bio Path USD 8.68M 819K Sep/2025
Brainstorm Cell Therapeutics USD 11.76M 757K Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.57M 2.29M Dec/2025
Immunic USD 38.36M 7.74M Mar/2026
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Minerva Neurosciences USD 2.29M 381K Dec/2025
RedHill Biopharma USD 22.29M 64K Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024